GlassScriptPhysician profile
James F Selph
NPI 1639226426
$3,614.83
in general payments reported to CMS, 2019-2025
9 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2021: $31.18 · 2022: $415 · 2023: $511 · 2024: $512 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,697.02 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $1,249.85 | 2023-2025 | Xcopri |
| Ucb, INC. | $228.03 | 2022-2024 | Briviact |
| Neuropace, INC. | $137.60 | 2024 | |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $110.86 | 2025 | |
| Argenx US, INC. | $27.64 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Cycle Pharmaceuticals INC | $22.73 | 2025 | Tascenso Odt, Bafiertam |
| Abbvie INC. | $16.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Selph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.